<DOC>
	<DOCNO>NCT00726661</DOCNO>
	<brief_summary>This multicenter , prospective observational cohort study ( OCS ) design follow patient locally recurrent metastatic breast cancer United States . Two cohort include : - Patients human epidermal growth factor receptor 2-negative ( HER2-negative ) disease receive first cytotoxic chemotherapy and/or target therapy ( approximately 825 patient ) - Patients hormone receptor-positive ( HR-positive ) disease receive first hormonal therapy advance disease ( approximately 425 patient ) Patients receive chemotherapy advance disease 8 week prior enrollment OCS eligible . A total approximately 1,250 patient enrol . Approximately 150 study site activate order achieve complete enrollment December 2010 .</brief_summary>
	<brief_title>An Observational Study Treatment Patterns Safety Outcomes Metastatic Locally Recurrent Breast Cancer ( VIRGO )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Signed Informed Consent Form Locally recurrent metastatic breast cancer Receipt first systemic cytotoxic chemotherapy and/or target therapy among HER2negative disease first hormone therapy among HRpositive disease treatment locally recurrent metastatic disease , within 8 week prior enrollment Exclusion Criteria Any medical condition , include mental illness substance abuse , deem investigator likely interfere patient 's ability provide inform consent comply treatment Any prior chemotherapy start 8 week prior enrollment treatment locally recurrent metastatic breast cancer Concurrent participation blind clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Locally Recurrent Breast Cancer</keyword>
	<keyword>Avastin</keyword>
</DOC>